Dexcom Inc., the leader in Continuous Glucose Monitoring
(CGM), has expanded with Canadian headquarters
BURNABY, BC, Jan. 11, 2017 /CNW/ - Dexcom, Inc. (NASDAQ: DXCM)
announced today that it is expanding its global presence with a new
Canadian headquarters in Burnaby, British
Columbia. The move aims to make it easier for more Canadians
to get started with CGM.
The launch of Dexcom (Canada)
Inc. means that Canadians living with diabetes can expect enhanced
customer experience and support, and the ability to purchase CGM
systems directly at Dexcom.com/Canada. This expansion reflects Dexcom's
mission and commitment to make it easier for Canadians living with
diabetes to experience the benefits of CGM for diabetes management.
Unlike blood glucose testing which gives a number for a single
point in time, CGM shows where glucose is, where it's going, and
how fast it's getting there – so patients can take quick action to
avoid dangerous glucose events or increase time spent in range.
"Dexcom is committed to transforming diabetes care and
management by delivering best-in-class solutions and by responding
to the needs of the community," explains Kevin Sayer, President and Chief Executive
Officer of Dexcom. "We are excited to share our dedication to
driving better outcomes and improved quality of life for people
living with diabetes in Canada."
Dexcom's new Canadian operation coincides with the launch of the
Dexcom G5 Mobile CGM system. It is the only CGM system in
North America approved to replace
painful fingerprick glucose testing for diabetes treatment
decisions, making it a significant leap forward in diabetes
management (fingerpricks are only needed every 12 hours to
calibrate). The Dexcom G5 is also the first and only fully
mobile CGM system that sends glucose data directly to a compatible
smart device. Securely transmitted every five minutes, this
glucose information allows for real-time diabetes management.
The Dexcom G5 Mobile CGM System is approved to use in patients
as young as 2 years of age, without the need for confirmatory
fingerpricks. And with the ability to share data, parents can
remotely monitor their child's glucose information and receive
alerts – for peace of mind while their child is beyond their
supervision.
"When I'm running long distances, hypos are a constant danger,"
explains endurance athlete Sébastien Sasseville, who lives with
Type 1 diabetes. "With the Dexcom G5, I get glucose readings every
five minutes so I know right where I stand, and where I'm headed. I
can act immediately to bring my levels into the right zone. And all
of this data is right on my phone, so I don't have to carry around
my receiver which was a hassle. But the best part is I don't have
to stop mid-run and do annoying, painful fingerpricks – I can
really just focus on the finish line." With the help of his Dexcom
CGM system, Sasseville has completed six Ironman Triathlons, run
the Sahara Race, and, most recently, run 7,200 kilometres across
Canada, the equivalent of 170
marathons.
The Dexcom G5 Mobile CGM System will be available within the
first quarter of 2017. And marking Dexcom's commitment to helping
Canadians access this technology, the company will be offering
monthly pricing options for the first time globally. Canadians
interested in the Dexcom G5 Mobile CGM system and staying up to
date on its launch are encouraged to visit Dexcom.com/Canada.
About Diabetes and Continuous Glucose Monitoring
With
diabetes, the body cannot produce or use the hormone insulin
effectively, causing a buildup of glucose, or sugar, in the blood.
People with diabetes who take insulin must monitor their blood
glucose levels frequently. Uncontrolled glucose can cause health
complications and even death.i,ii
Continuous glucose monitoring (CGM) is considered the most
significant breakthrough in diabetes management in the past 40
years.iii CGM is important because, in addition to
providing the glucose level, it provides the direction and rate of
glucose change with the push of a button and alerts users when
glucose is too low or too high with built-in and customizable
alarms. A recent study showed that after one year, patients with
type 1 diabetes who used CGM alone had significant A1C reductions
regardless of the type of insulin delivery method used, including
insulin pumps.iv
About Dexcom, Inc.
Dexcom, Inc., headquartered in San Diego, CA, and has
operations in Canada, is dedicated
to helping people better manage their diabetes by developing and
marketing continuous glucose monitoring (CGM) products and tools
for adult and pediatric patients. With exceptional
performance, patient comfort and lifestyle flexibility at the heart
of its technology, users have consistently
ranked Dexcom highest in customer satisfaction and
loyalty.v For more information on the Dexcom CGM,
visit www.dexcom.com.
References
i Hyperglycemia (High blood glucose).
American Diabetes Association Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html.
Updated August 5, 2013. Accessed
December 3, 2013.
ii Hypoglycemia (Low blood glucose). American Diabetes Association
Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html.
Updated July 16, 2013. Accessed
December 3, 2013.
iii Clarke SF and Foster JR. A history of blood glucose meters and
their role in self-monitoring of diabetes mellitus. Br J Biomed
Sci. 2012;(3)2:83-93.
iv J. Soupal, J. Skrha Prazny, M. Flekac, L. Petruzelkova, J.
Skrha, et al. Comparison of different treatment modalities for Type
1 diabetes including Sensor-Augmented Insulin Regimens (SAIR), in
52 weeks of follow ups: A COMISAIR Study. Diabetes Technology and
Therapeutics. Vol 18, No. 9, Sept.
2016.
v dQ&A research, 2009-2016
For high resolution logo, please click here
SOURCE Dexcom, Inc.